Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene.
Sun's UV radiation rendered harmless by skin pigment
9/30/2014
Researchers at Lund University in Sweden and other institutions have worked out how the pigment of the skin manages to protect the body from the sun's dangerous UV rays.
Cancer survivors excluded from lung cancer clinical trials
9/30/2014
Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center.
Survey reveals emotional exhaustion affects many cancer specialists
9/30/2014
Across Europe, more than 70% of young cancer specialists are showing signs of burnout, the largest survey of its kind has revealed.
Potent new cancer drugs likely with new protein 'map'
9/30/2014
Imperial chemists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped.
What are the top 10 leading causes of death in the US?
9/30/2014
The leading top 10 causes of death in the US account for nearly 75% of all deaths in the country. How many of these causes could be prevented and how? MNT takes a look.
Helping breast cancer patients make choices about reconstruction
9/30/2014
Information plus patient preferences can help in sorting through reconstruction options, according to plastic and reconstructive surgeryDecision analysis techniques can help surgeons and patients...
New estrogen-related breast cancer mechanism detected
9/29/2014
Estrogen prepares cells to divide and even resist drugs for estrogen-positive breast cancers, according to new research investigating the role of the unfolded-protein response.
Customising chemotherapy in lung cancer
9/29/2014
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in...
Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous lung cancer
9/29/2014
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free...